Bone turnover markers: defining a therapeutic target

Chubb, S.A. Paul, Byrnes, Elizabeth, Manning, Laurens, Golledge, Jonathan, Ebeling, Peter R., Flicker, Leon, Yeap, Bu B., and Vasikaran, Samuel D. (2017) Bone turnover markers: defining a therapeutic target. Clinical Biochemistry, 50 (3). pp. 162-163.

[img] PDF (Published Version) - Published Version
Restricted to Repository staff only

View at Publisher Website:


[Extract] Bone turnover markers (BTM) in widespread clinical use include urine NTX, plasma βCTX and plasma total procollagen type 1 amino terminal propeptide (P1NP). An important application of BTMs is in monitoring anti-osteoporosis therapy, and specifically, in indicating whether current therapy is likely to achieve optimal reduction of fracture risk. Of the 3 BTMs mentioned above, only urine NTX (as NTX/creatinine ratio) has an evidence-based threshold indicating optimum fracture risk reductio. However measurement of βCTX and P1NP is preferred owing to their smaller biological variation and greater response to treatment. We recently published provisional therapeutic thresholds for plasma βCTX assays that were equivalent to the urine NTX/creatinine ratio indicative of maximal fracture risk reduction for patients treated with risedronate.

Item ID: 56262
Item Type: Article (Commentary)
ISSN: 1873-2933
Keywords: P1NP, treatment target, fracture risk reduction
Date Deposited: 28 Nov 2018 07:52
FoR Codes: 11 MEDICAL AND HEALTH SCIENCES > 1102 Cardiovascular Medicine and Haematology > 110299 Cardiovascular Medicine and Haematology not elsewhere classified @ 100%
SEO Codes: 92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920103 Cardiovascular System and Diseases @ 100%
Downloads: Total: 1
More Statistics

Actions (Repository Staff Only)

Item Control Page Item Control Page